Exploring Schiff Bases as Promising Alternatives to Traditional Drugs in the In Silico Treatment of Anti-Leishmaniasis as Trypanothione Reductase Inhibitors
Leishmaniasis, caused by the protozoan <i>Leishmania</i> spp. and transmitted by sandflies, affects 2 million people worldwide yearly and is recognized as a global problem by the WHO. Current treatments, including amphotericin B, Pentamidine, and Glucantime, show limited efficacy and ser...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Proceedings |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2504-3900/102/1/55 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Leishmaniasis, caused by the protozoan <i>Leishmania</i> spp. and transmitted by sandflies, affects 2 million people worldwide yearly and is recognized as a global problem by the WHO. Current treatments, including amphotericin B, Pentamidine, and Glucantime, show limited efficacy and serious side effects. Trypanothione reductase is a promising protein target for developing new promising drugs against Leishmaniasis. This study explores Schiff base compounds as potential alternatives to current treatments by inhibiting trypanothione reductase. Thirty-nine structures from the PubChem database were selected and analyzed using AutoDock Vina 1.1, an in silico molecular docking tool. Promising Schiff base candidates, indicated as compound <b>21</b> (3-Quinolinamine, N-(2-quinolinylmethylene)-, compound <b>24</b> (1,3-Bis[(E)-(2-Amino-4-Ethyl-5-Hydroxy-Phenyl)Methyleneamino]Urea, and compound <b>39</b> (Naphtaldehyde disulfide Schiff base), exhibited significant inhibitory binding affinity against trypanothione reductase, outperforming commercial inhibitors. Therefore, the present study proposes alternative Schiff base compounds for treating Leishmaniasis. |
|---|---|
| ISSN: | 2504-3900 |